Institute of Biostructure and Bioimaging, Department of Biomorphological Sciences, University Federico II, Naples, Italy
Department of Neurological Sciences, School of Biotechnological Sciences, University Federico II, Naples, Italy
Department of Clinical and Experimental Medicine, University Federico II, Naples, Italy
References: Davies, P., Maloney, A.J., Selective loss of central cholinergic neurons in Alzheimer's disease (1976) Lancet, 2 (8000), p. 140
Francis, P.T., Palmer, A.M., Snape, M., Wilcock, G.K., The cholinergic hypothesis of Alzheimer's disease: A review of progress (1999) J Neurol Neurosurg Psychiatry, 66 (2), pp. 137-147
Volkow, N.D., Rosen, B., Farde, L., Imaging the living human brain: Magnetic resonance imaging and positron emission tomography (1997) Proc Natl Acad Sci USA, 94 (7), pp. 2787-2788
Minoshima, S., Frey, K.A., Cross, D.J., Kuhl, D.E., Neurochemical imaging of dementias (2004) Semin Nucl Med, 34 (1), pp. 70-82
Elsinga, P.H., Radiopharmaceutical chemistry for positron emission tomography (2002) Methods, 27, pp. 208-217
Slifstein, M., Laruelle, M., Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers (2001) Nucl Med Biol, 28, pp. 595-608
Laruelle, M., Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review (2000) J Cereb Blood Flow Metab, 20 (3), pp. 423-451
Nordberg, A., Neuroreceptor changes in Alzheimer disease (1992) Cerebrovasc Brain Metab Rev, 4 (4), pp. 303-328
Quarantelli, M., Berkouk, K., Prinster, A., Landeau, B., Svarer, C., Balkay, L., Alfano, B., Salvatore, M., Integrated software for the analysis of brain PET/SPECT studies with partial-volume-effect correction (2004) J Nucl Med, 45 (2), pp. 192-201
Sarter, M., Bruno, J.P., Cognitive functions of cortical acetylcholine: Toward a unifying hypothesis (1997) Brain Res Brain Res Rev, 23 (1-2), pp. 28-46
Perry, E., Walker, M., Grace, J., Perry, R., Acetylcholine in mind: A neurotransmitter correlate of consciousness? (1999) Trends Neurosci, 22 (6), pp. 273-280
Bentley, P., Husain, M., Dolan, R.J., Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory (2004) Neuron, 41 (6), pp. 969-982
Geula, C., Mesulam, M.M., Cholinergic systems and related neuropathological predilection patterns in Alzheimer's disease (1994) Alzheimer's Disease., pp. 263-291. , In: Terry, R.D., Katzman, R., Bick, K.L., eds, New York: Raven Press
Ruberg, M., Rieger, F., Villageois, A., Bonnet, A.M., Agid, Y., Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease (1986) Brain Res, 362 (1), pp. 83-91
Perry, E.K., Haroutunian, V., Davis, K.L., Levy, R., Lantos, P., Eagger, S., Honavar, M., Perry, R.H., Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease (1994) Neuroreport, 5 (7), pp. 747-749
Warren, N.M., Piggott, M.A., Perry, E.K., Burn, D.J., Cholinergic systems in progressive supranuclear palsy (2005) Brain, 128 (2), pp. 239-249
Mesulam, M., Siddique, T., Cohen, B., Cholinergic denervation in a pure multi-infarct state: Observations on CADASIL (2003) Neurology, 60 (7), pp. 1183-1185
Kuhl, D.E., Koeppe, R.A., Fessler, J.A., Minoshima, S., Ackermann, R.J., Carey, J.E., Gildersleeve, D.L., Wieland, D.M., In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM (1994) J Nucl Med, 35 (3), pp. 405-410
Shinotoh, H., Fukushi, K., Nagatsuka, S., Irie, T., Acetylcholinesterase imaging: Its use in therapy evaluation and drug design (2004) Curr Pharm des, 10 (13), pp. 1505-1517
Atack, J.R., Perry, E.K., Bonham, J.R., Boakes, R., Candy, J.M., Loss and recovery of acetylcholinesterase molecular forms in the fornix-lesioned rat hippocampus (1987) Neurosci Lett, 79 (1-2), pp. 179-184
Fowler, J.S., Ding, Y.S., Volkow, N.D., Radiotracers for positron emission tomography imaging (2003) Semin Nucl Med, 33 (1), pp. 14-27
Kuhl, D.E., Minoshima, S., Fessler, J.A., Frey, K.A., Foster, N.L., Ficaro, E.P., Wieland, D.M., Koeppe, R.A., In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease (1996) Ann Neurol, 40 (3), pp. 399-410
Iyo, M., Namba, H., Fukushi, K., Shinotoh, H., Nagatsuka, S., Suhara, T., Sudo, Y., Irie, T., Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease (1997) Lancet, 349 (9068), pp. 1805-1809
Shinotoh, H., Namba, H., Fukushi, K., Nagatsuka, S., Tanaka, N., Aotsuka, A., Ota, T., Irie, T., Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study (2000) Ann Neurol, 48 (2), pp. 194-200
Herholz, K., Weisenbach, S., Zundorf, G., Lenz, O., Schroder, H., Bauer, B., Kalbe, E., Heiss, W.D., In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease (2004) Neuroimage, 21 (1), pp. 136-143
Rinne, J.O., Kaasinen, V., Jarvenpaa, T., Nagren, K., Roivainen, A., Yu, M., Oikonen, V., Kurki, T., Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease (2003) J Neurol Neurosurg Psychiatry, 74 (1), pp. 113-115
Bohnen, N.I., Kaufer, D.I., Ivanco, L.S., Lopresti, B., Koeppe, R.A., Davis, J.G., Mathis, C.A., Dekosky, S.T., Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study (2003) Arch Neurol, 60 (12), pp. 1745-1748
Eggers, C., Herholz, K., Kalbe, E., Heiss, W.D., Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease (2006) Neurosci Lett, 408 (1), pp. 46-50
Poirier, J., Delisle, M.C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Gauthier, S., Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease (1995) Proc Natl Acad Sci, 92 (26), pp. 12260-12264
Gsell, W., Strein, I., Riederer, P., The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared (1996) J Neural Transm Suppl, 47, pp. 73-101
Davis, K.L., Mohs, R.C., Marin, D., Purohit, D.P., Perl, D.P., Lantz, M., Austin, G., Haroutunian, V., Cholinergic markers in elderly patients with early signs of Alzheimer disease (1999) JAMA, 281 (15), pp. 1401-1406
Hu, L., Wong, T.P., Cote, S.L., Bell, K.F., Cuello, A.C., The impact of Abeta-plaques on cortical cholinergic and non-cholinergic pre-synaptic boutons in Alzheimer's disease-like transgenic mice (2003) Neuroscience, 121 (2), pp. 421-432
Shinotoh, H., Aotsuka, A., Fukushi, K., Nagatsuka, S., Tanaka, N., Ota, T., Tanada, S., Irie, T., Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET (2001) Neurology, 56 (3), pp. 408-410
Volkow, N.D., Ding, Y.S., Fowler, J.S., Gatley, S.J., Imaging brain cholinergic activity with positron emission tomography: Its role in the evaluation of cholinergic treatments in Alzheimer's dementia (2001) Biol Psychiatry, 49 (3), pp. 211-220
Flynn, D.D., Ferrari-Dileo, G., Mash, D.C., Levey, A.I., Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease (1995) J Neurochem, 64 (4), pp. 1888-1891
Kendziorra, K., Meyer, P., Wolf, H., Barthel, H., Hesse, S., Seese, A., Sorger, D., Sabri, O., Cerebral nicotinic acetylcholine receptors in patients with Alzheimer's disease assessed with 2-[18F]F-A85380 PET-correlations to dementia severity (2006) Neuroimage, 31 (2), pp. T39
O'Brien, J.T., Colloby, S.J., Pakrasi, S., Perry, E.K., Pimlott, S.L., Wyper, D.J., McKeith, I.G., Williams, E.D., Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography (2007) J Neurol Neurosurg Psychiatry, 78 (4), pp. 356-362
Pimlott, S.L., Piggott, M., Owens, J., Greally, E., Court, J.A., Jaros, E., Perry, R.H., Wyper, D., Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: In vitro binding study using 5-[(125)i]-a-85380 (2004) Neuropsychopharmacology, 29 (1), pp. 108-116
Hilker, R., Thomas, A.V., Klein, J.C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A.H., Heiss, W.D., Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways (2005) Neurology, 65 (11), pp. 1716-1722
Herholz, K., PET studies in dementia (2003) Ann Nucl Med, 17 (2), pp. 79-89
Hirano, S., Shinotoh, H., Kobayashi, T., Tsuboi, Y., Wszolek, Z.K., Aotsuka, A., Tanaka, N., Irie, T., Brain acetylcholinesterase activity in FTDP-17 studied by PET (2006) Neurology, 66 (8), pp. 1276-1277
Pappata, S., Traykov, L., Tavitian, B., Damier, P., Dubois, B., Jobert, A., Crouzel, C., Di Giamberardino, L., Striatal reduction of acetylcholinesterase (AChE) in patients with progressive supranuclear palsy (PSP) as measured by PET and 11C-physostigmine (11C-PHY) (1997) J Cereb Blood Flow and Metab, 17 (1), pp. S687
Pappata, S., Tavitian, B., Traykov, L., Jobert, A., Dalger, A., Mangin, J.F., Crouzel, C., Digiamberardino, L., In vivo imaging of human cerebral acetylcholinesterase (1996) J Neurochem, 67 (2), pp. 876-879
Emre, M., Dementia associated with Parkinson's disease (2003) Lancet Neurol, 2 (4), pp. 229-237
Farr, S.A., Flood, J.F., Morley, J.E., The effect of cholinergic, GABAergic, serotonergic, and glutamatergic receptor modulation on post-trial memory processing in the hippocampus (2000) Neurobiol Learn Mem, 73 (2), pp. 150-167
Maubach, K., GABA(A) receptor subtype selective cognition enhancers (2003) Curr Drug Targets CNS Neurol Disord, 2 (4), pp. 233-239
Lanctot, K.L., Herrmann, N., Mazzotta, P., Khan, L.R., Ingber, N., GABAergic function in Alzheimer's disease: Evidence for dysfunction and potential as a therapeutic target for the treatment of behaviorial and psychological symptoms of dementia (2004) Can J Psychiatry, 49 (7), pp. 439-453
Beer, H.F., Bläuenstein, P.A., Hasler, P.H., Delaloye, B., Riccabona, G., Bangerl, I., Hunkeler, W., Schubiger, P.A., In vitro and in vivo evaluation of iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors (1990) J Nucl Med, 31 (6), pp. 1007-1014
Meyer, M., Koeppe, R.A., Frey, K.A., Foster, N.L., Kuhl, D.E., Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease (1995) Arch Neurol, 52 (3), pp. 314-317
Ohyama, M., Senda, M., Ishiwata, K., Kitamura, S., Mishina, M., Ishii, K., Toyama, H., Katayama, Y., Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF (1999) Ann Nucl Med, 13 (5), pp. 309-315
Soricelli, A., Postiglione, A., Grivet-Fojaja, M.R., Mainenti, P.P., Discepolo, A., Varrone, A., Salvatore, M., Lassen, N.A., Reduced cortical distribution volume of iodine-123 iomazenil in Alzheimer's disease as a measure of loss of synapses (1996) Eur J Nucl Med, 23 (10), pp. 1323-1328
Fukuchi, K., Hashikawa, K., Seike, Y., Moriwaki, H., Oku, N., Ishida, M., Fujita, M., Nishimura, T., Comparison of iodine-123-iomazenil SPECT and technetium-99m-HMPAO-SPECT in Alzheimer's disease (1997) J Nucl Med, 38 (3), pp. 467-470
Pappata, S., Varrone, A., Milan, G., Sansone, V., Iavarone, A., Panico, M.R., Quarantelli, M., Salvatore, M., SPECT study of GABAA/BZD receptors and cerebral blood flow in mild cognitive impairment (MCI) (2006) Neuroimage, 31 (2), pp. T169
Foster, N.L., Minoshima, S., Johanns, J., Little, R., Heumann, M.L., Kuhl, D.E., Gilman, S., PET measures of benzodiazepine receptors in progressive supranuclear palsy (2000) Neurology, 54 (9), pp. 1768-1773
Ihara, M., Tomimoto, H., Ishizu, K., Mukai, T., Yoshida, H., Sawamoto, N., Inoue, M., Fukuyama, H., Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis: A positron emission tomography study (2004) Stroke, 35 (4), pp. 942-947
Bell, K.F., Ducatenzeiler, A., Ribeiro-Da-Silva, A., Duff, K., Bennett, D.A., Claudio Cuello, A., The amyloid pathology progresses in a neurotransmitter-specific manner (2006) Neurobiol Aging, 27 (11), pp. 1644-1657
Hendricksen, M., Thomas, A.J., Ferrier, I.N., Ince, P., O'Brien, J.T., Neuropathological study of the dorsal raphe nuclei in late-life depression and Alzheimer's disease with and without depression (2004) Am J Psychiatry, 161 (6), pp. 1096-1102
Meltzer, C.C., Smith, G., Dekosky, S.T., Pollock, B.G., Mathis, C.A., Moore, R.Y., Kupfer, D.J., Reynolds III, C.F., Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging (1998) Neuropsychopharmacology, 18 (6), pp. 407-430
Huey, E.D., Putnam, K.T., Grafman, J., A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia (2006) Neurology, 66 (1), pp. 17-22
Blin, J., Baron, J.C., Dubois, B., Crouzel, C., Fiorelli, M., Attar-Levy, D., Pillon, B., Agid, Y., Loss of brain 5-HT2 receptors in Alzheimer's disease. in vivo assessment with positron emission tomography and [18F]setoperone (1993) Brain, 116 (3), pp. 497-510
Meltzer, C.C., Price, J.C., Mathis, C.A., Greer, P.J., Cantwell, M.N., Houck, P.R., Mulsant, B.H., Reynolds III, C.F., PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders (1999) Am J Psychiatry, 156 (12), pp. 1871-1878
Versijpt, J., Van Laere, K.J., Dumont, F., Decoo, D., Vandecapelle, M., Santens, P., Goethals, I., Korf, J., Imaging of the 5-HT2A system: Age-, gender-, and Alzheimer's disease-related findings (2003) Neurobiol Aging, 24 (4), pp. 553-561
Hasselbalch, S.G., Madsen, K., Svarer, C., Pinborg, L.H., Holm, S., Paulson, O.B., Waldemar, G., Knudsen, G.M., Reduced 5-HT(2A) receptor binding in patients with mild cognitive impairment (2007) Neurobiol Aging, , Jun 1. [Epub ahead of print]
Kepe, V., Barrio, J.R., Huang, S.C., Ercoli, L., Siddarth, P., Shoghi-Jadid, K., Cole, G.M., Phelps, M.E., Serotonin 1A receptors in the living brain of Alzheimer's disease patients (2006) Proc Natl Acad Sci, 103 (3), pp. 702-707
Franceschi, M., Anchisi, D., Pelati, O., Zuffi, M., Matarrese, M., Moresco, R.M., Fazio, F., Perani, D., Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration (2005) Ann Neurol, 57 (2), pp. 216-225
Robbins, T.W., Dopamine and cognition (2003) Curr Opin Neurol, 16 (2), pp. S1-S2
Piggott, M.A., Marshall, E.F., Thomas, N., Lloyd, S., Court, J.A., Jaros, E., Burn, D., Perry, E.K., Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: Rostrocaudal distribution (1999) Brain, 122 (8), pp. 1449-1468
Pillon, B., Czernecki, V., Dubois, B., Dopamine and cognitive function (2003) Curr Opin Neurol, 16 (2), pp. S17-S22
Cropley, V.L., Fujita, M., Innis, R.B., Nathan, P.J., Molecular imaging of the dopaminergic system and its association with human cognitive function (2006) Biol Psychiatry, 59 (10), pp. 898-907
Marie, R.M., Barre, L., Dupuy, B., Viader, F., Defer, G., Baron, J.C., Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease (1999) Neurosci Lett, 260 (2), pp. 77-80
Cheesman, A.L., Barker, R.A., Lewis, S.J., Robbins, T.W., Owen, A.M., Brooks, D.J., Lateralisation of striatal function: Evidence from 18F-dopa PET in Parkinson's disease (2005) J Neurol Neurosurg Psychiatry, 76 (9), pp. 1204-1210
Rinne, J.O., Portin, R., Ruottinen, H., Nurmi, E., Bergman, J., Haaparanta, M., Solin, O., Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study (2000) Arch Neurol, 57 (4), pp. 470-475
Ito, K., Nagano-Saito, A., Kato, T., Arahata, Y., Nakamura, A., Kawasumi, Y., Hatano, K., Brooks, D.J., Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: A 6-[18F]fluoro-L-dopa PET study (2002) Brain, 125 (6), pp. 1358-1365
McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., Dickson, D., Reid, W., Dementia with Lewy bodies (2004) Lancet Neurol, 3 (1), pp. 19-28. , International Psychogeriatric Association Expert Meeting on DLB
Walker, Z., Costa, D.C., Walker, R.W., Shaw, K., Gacinovic, S., Stevens, T., Livingston, G., Katona, C.L., Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic pre-synaptic ligand (2002) J Neurol Neurosurg Psychiatry, 73 (2), pp. 134-140
Hu, X.S., Okamura, N., Arai, H., Higuchi, M., Matsui, T., Tashiro, M., Shinkawa, M., Sasaki, H., 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies (2000) Neurology, 55 (10), pp. 1575-1577
Colloby, S.J., O'Brien, J.T., Fenwick, J.D., Firbank, M.J., Burn, D.J., McKeith, I.G., Williams, E.D., The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease (2004) Neuroimage, 23 (3), pp. 956-966
Gilman, S., Koeppe, R.A., Little, R., An, H., Junck, L., Giordani, B., Persad, C., Wernette, K., Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease (2004) Ann Neurol, 55 (6), pp. 774-780
Walker, Z., Jaros, E., Walker, R.W., Lee, L., Costa, D.C., Livingston, G., Ince, P., Katona, C.L., Dementia with lewy bodies: A comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy (2007) J Neurol Neurosurg Psychiatry, , Mar 12. [Epub ahead of print]
McKeith, I., O'Brien, J., Walker, Z., Tatsch, K., Booij, J., Darcourt, J., Padovani, A., Reininger, C., Sensitivity and specificity of dopamine transporter imaging with (123)I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study (2007) Lancet Neurol, 6 (4), pp. 305-313. , for the DLB Study Group
Colloby, S.J., Williams, E.D., Burn, D.J., Lloyd, J.J., McKeith, I.G., O'Brien, J.T., Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT (2005) Eur J Nucl Med Mol Imaging, 32 (10), pp. 1176-1185
Plotkin, M., Amthauer, H., Klaffke, S., Kuhn, A., Ludemann, L., Arnold, G., Wernecke, K.D., Venz, S., Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients (2005) J Neural Transm, 112 (5), pp. 677-692
Rinne, J.O., Sahlberg, N., Ruottinen, H., Nagren, K., Lehikoinen, P., Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography (1998) Neurology, 50 (1), pp. 152-156
Tyrrell, P.J., Sawle, G.V., Ibanez, V., Bloomfield, P.M., Leenders, K.L., Frackowiak, R.S., Rossor, M.N., Clinical and positron emission tomographic studies in the 'extrapyramidal syndrome' of dementia of the Alzheimer type (1990) Arch Neurol, 47 (12), pp. 1318-1323
Pizzolato, G., Chierichetti, F., Fabbri, M., Cagnin, A., Dam, M., Ferlin, G., Battistin, L., Reduced striatal dopamine receptors in Alzheimer's disease: Single photon emission tomography study with the D2 tracer [123I]-IBZM (1996) Neurology, 47 (4), pp. 1065-1068
Kemppainen, N., Ruottinen, H., Nagren, K., Rinne, J.O., PET shows that striatal dopamine D1 and D2 receptors are differentially affected in AD (2000) Neurology, 55 (2), pp. 205-209
Meguro, K., Yamaguchi, S., Itoh, M., Fujiwara, T., Yamadori, A., Striatal dopamine metabolism correlated with frontotemporal glucose utilization in Alzheimer's disease: A double-tracer PET study (1997) Neurology, 49 (4), pp. 941-945
Tanaka, Y., Meguro, K., Yamaguchi, S., Ishii, H., Watanuki, S., Funaki, Y., Yamaguchi, K., Itoh, M., Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease (2003) Ann Nucl Med, 17 (7), pp. 567-573
Kemppainen, N., Laine, M., Laakso, M.P., Kaasinen, V., Nagren, K., Vahlberg, T., Kurki, T., Rinne, J.O., Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease (2003) Eur J Neurosci, 18 (1), pp. 149-154
Sperfeld, A.D., Collatz, M.B., Baier, H., Palmbach, M., Storch, A., Schwarz, J., Tatsch, K., Ludolph, A.C., FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation (1999) Ann Neurol, 46 (5), pp. 708-715
Pal, P.K., Wszolek, Z.K., Kishore, A., De La Fuente-Fernandez, R., Sossi, V., Uitti, R.J., Dobko, T., Stoessl, A.J., Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene) (2001) Parkinsonism Relat Disord, 7 (2), pp. 81-88
Rinne, J.O., Laine, M., Kaasinen, V., Norvasuo-Heila, M.K., Nagren, K., Helenius, H., Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia (2002) Neurology, 58 (10), pp. 1489-1493
Frisoni, G.B., Pizzolato, G., Bianchetti, A., Chierichetti, F., Ferlin, G., Battistin, L., Trabucchi, M., Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: Preliminary results (1994) Acta Neurol Scand, 89 (3), pp. 199-203
Baron, J.C., Maziere, B., Loc'H, C., Cambon, H., Sgouropoulos, P., Bonnet, A.M., Agid, Y., Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy (1986) J Cereb Blood Flow Metab, 6 (2), pp. 131-136
Brooks, D.J., PET studies in progressive supranuclear palsy (1994) J Neural Transm Suppl, 42, pp. 119-134
Ginovart, N., Lundin, A., Farde, L., Halldin, C., Backman, L., Swahn, C.G., Pauli, S., Sedvall, G., PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease (1997) Brain, 120, pp. 503-514
Lawrence, A.D., Weeks, R.A., Brooks, D.J., Andrews, T.C., Watkins, L.H., Harding, A.E., Robbins, T.W., Sahakian, B.J., The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease (1998) Brain, 121, pp. 1343-1355
Yoshita, M., Taki, J., Yokoyama, K., Noguchi-Shinohara, M., Matsumoto, Y., Nakajima, K., Yamada, M., Value of 123I-MIGB radioactivity in the differential diagnosis of DLB from AD (2006) Neurology, 66 (12), pp. 1850-1854
Pappata, S., Dehaene, S., Poline, J.B., Gregoire, M.C., Jobert, A., Delforge, J., Frouin, V., Syrota, A., In vivo detection of striatal dopamine release during reward: A PET study with [(11)C]raclopride and a single dynamic scan approach (2002) Neuroimage, 16 (4), pp. 1015-1027
Masters, C.L., Cappai, R., Barnham, K.J., Villemagne, V.L., Molecular mechanisms for Alzheimer's disease: Implications for neuroimaging and therapeutics (2006) J Neurochem, 97 (6), pp. 1700-1725
Cagnin, A., Kassiou, M., Meikle, S.R., Banati, R.B., In vivo evidence for microglial activation in neurodegenerative dementia (2006) Acta Neurol Scand Suppl, 185, pp. 107-114
In vivo imaging of neurotransmission and brain receptors in dementia
Positron emission tomography (PET) and single photon emission tomography (SPECT) are the most sensitive techniques to study, in vivo, neurotransmitter systems in normal human brain and in diseases. These methods have been applied over the last years to explore the integrity of cholinergic, serotonergic, GABAergic, and dopaminergic systems in Alzheimer's disease (AD) and in other dementias. The results of these investigations have provided new insights into the neurotransmission involvement in these disorders. Moreover, these methods provide objective quantitative markers for monitoring the progression of disease and the effects of therapies. The pathophysiological and clinical relevance of results from these studies are reviewed and the potential role in early and differential diagnosis discussed. New emerging radiotracers/methods for future investigations of neurochemical processes are delineated.
In vivo imaging of neurotransmission and brain receptors in dementia
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(1002 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote